Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | FLT3 | P36888 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4723636 | 0.88 | GPR119 (0.62) | GPR119CYP2C9FLT3CDK2CDK6 | |
| SCHEMBL4719405 | 0.88 | GPR119 (0.48) | GPR119FLT3CDK2CDK6 | |
| SCHEMBL389295 | 0.88 | GPR119 (0.74) | GPR119CYP2C9KCNH2 | |
| SCHEMBL4719420 | 0.86 | GPR119 (0.61) | GPR119CYP2C9FLT3CDK2CDK6 | |
| SCHEMBL4721651 | 0.85 | GPR119 (0.60) | GPR119CYP2C9FLT3CDK2CDK6 | |
| SCHEMBL4724133 | 0.85 | GPR119 (0.51) | GPR119CYP2C9FLT3CDK2CDK6 | |
| SCHEMBL4723690 | 0.84 | GPR119 (0.49) | GPR119CYP2C9FLT3CDK2CDK6 | |
| SCHEMBL4723272 | 0.84 | GPR119 (0.46) | GPR119FLT3CDK2CDK6 | |
| SCHEMBL4723387 | 0.84 | GPR119 (0.49) | GPR119FLT3CDK2CDK6 | |
| SCHEMBL4721027 | 0.83 | GPR119 (0.55) | GPR119CYP2C9FLT3CDK2CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756084-B1 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2008-11-26 | — | — | EP | claimed |